EVM
TVRD

Eaton Vance Management’s Tvardi Therapeutics TVRD Stock Holding History

Eaton Vance Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-13
Closed -$6K – 2775
2021
Q4 		$6K Sell
13
-3
-19% -$1.51K ﹤0.01% 2624
2021
Q3 		$0 Buy
16
+9
+129% +$4.51K ﹤0.01% 2763
2021
Q2 		$3K Sell
7
-6
-46% -$3.8K ﹤0.01% 2693
2021
Q1 		$10K Buy
+13
New +$8.9K ﹤0.01% 2373

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Eaton Vance Management's TVRD Position: Q1 2022 in Review

Eaton Vance Management sold out of Tvardi Therapeutics (TVRD) in Q1 2022, closing a stake of 13 shares — an estimated $6K sold.

Eaton Vance Management first reported a position in TVRD in Q1 2021 and held it in 4 quarters. The position peaked at $10K in Q1 2021. 183 funds tracked by Wall St. Rank hold TVRD as of Q1 2022.

  • Eaton Vance Management reported no remaining Tvardi Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Eaton Vance Management sold 13 Tvardi Therapeutics shares in Q1 2022, an estimated $6K.
  • Eaton Vance Management first reported a position in Tvardi Therapeutics in Q1 2021 and held it in 4 quarters.
  • Eaton Vance Management's Tvardi Therapeutics position peaked at $10K in Q1 2021.
  • 183 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.